Morphine for the symptomatic reduction of chronic breathlessness: the case for controlled release.
- LIPPINCOTT WILLIAMS & WILKINS
- Publication Type:
- Journal Article
- Current opinion in supportive and palliative care, 2020, 14, (3), pp. 177-181
- Issue Date:
|Morphine for the symptomatic reduction of chronic breathlessess - the case for controlled release_Author's Copy.pdf||Accepted Manuscript||397.99 kB|
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is being processed and is not currently available.
Purpose of reviewClinicians who seek to reduce the symptomatic burden of chronic breathlessness by initiating regular low-dose morphine has the choice of immediate or sustained-release formulations - which will be better for this often frail population, and which has the more robust evidence to inform its prescription? Both formulations can be used.
Recent findingsFor chronic breathlessness, three factors consistently favour the use of regular, low-dose, sustained-release morphine over immediate-release formulations: SUMMARY: As the evidence base expands for the symptomatic reduction of chronic breathlessness, pharmacological interventions will play a part. Using the best available evidence underpins patient-centred approaches that seek to predictably maximize the net effect.As such, the weight of evidence in patient-centred clinical care favours the use of regular, low-dose sustained-release morphine for the symptomatic reduction of chronic breathlessness.
Please use this identifier to cite or link to this item: